Pediatric Drugs and Vaccines: Market Research Report

February 2018 | 431 pages | ID: PE4F0D08DF7EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Pediatric Drugs and Vaccines in US$ Million by the following Therapeutic Class: Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs, and Other Pediatric Drugs. The Pediatric Vaccines market is also analyzed by the following Type: Combinations, Hepatitis, MMR, Varicella, Poliovirus, Pneumococcal, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs.

The report profiles 90 companies including many key and niche players such as -

• Abbott Laboratories
• Allergan, Inc.
• Amgen, Inc.
• AstraZeneca Plc
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

Pediatrics: A Highly Underserved and Undervalued Group

Table 1. Global New Births (in Millions) per Annum by Geographic Region (includes corresponding Graph/Chart)

Table 2. Global Birth Rates: Number of Births (per ‘000 Population) for the Years 1990, 1995, 2000, 2005, 2010, and 2015 (includes corresponding Graph/Chart)

Table 3. Top 25 Countries in Global Birth Rates Worldwide (2014): Ranked by Number of Births per 1000 Population (includes corresponding Graph/Chart)

Table 4. Top 25 Countries in terms of Fertility Rates Worldwide (2014) - Ranked by Number of Children Born Per Woman (includes corresponding Graph/Chart)

Pediatric Drugs Market – An Abode of Opportunities
The United States: Largest Market for Pediatric Drugs and Vaccines
Developing Markets to Witness Faster Growth

Table 5. Healthcare Spending as a Percentage of GDP by Region (2016E) (includes corresponding Graph/Chart)

Table 6. Per-Capita Healthcare Expenditure in US$ for Select Countries/Regions (2014) (includes corresponding Graph/Chart)

Table 7. Developing Regions Lead Children Population Globally (includes corresponding Graph/Chart)

Table 8. Global Under 15 Years Population (2016): Percentage Breakdown by Gender (includes corresponding Graph/Chart)

Table 9. Population of Children in the Age Group of 0-15 Years as a Percentage of Total Population by Region/Country (2016) (includes corresponding Graph/Chart)

Table 10. Proportion of Children in the 0-15 Years Age Group by Country in Europe (2016) (includes corresponding Graph/Chart)

Table 11. Proportion of Children in the 0-15 Years Age Group by Country in Asia-Pacific (2016) (includes corresponding Graph/Chart)

Table 12. Proportion of Children in the 0-15 Years Age Group by Country in Latin America (2016) (includes corresponding Graph/Chart)

Table 13. Proportion of Children in the 0-15 Years Age Group by Country in the Middle East (2016) (includes corresponding Graph/Chart)

Antibiotics: Largest Selling Drug Classes

Table 14. Global Pediatric Drugs Market by Therapeutic Class: Segments Ranked by Growth (includes corresponding Graph/Chart)

Pediatric Vaccines Market – On High Growth Trajectory
Supply and Demand Dynamics of the Global Vaccine Market

Table 15. Global Vaccine Market by Countries’ Economic Status (2016): Percentage Share Breakdown for High-income, Middle-Income (Upper & Lower), and Low-income Nations (includes corresponding Graph/Chart)

UNICEF Addresses BCG Vaccine Supply Shortage
Access to Vaccines Index: Aiding Increased Access to Vaccines
Recent Advancements/Achievements in the Pediatric Vaccines Space

2. GROWTH DRIVERS AND MARKET TRENDS

Pediatric Exclusivity Drives Manufacturers’ Interest
Pediatric Exclusitivity Granted to Branded Drugs
New Product Approvals and Pipeline – A Key Growth Propeller
Recent Pediatric Drug Approvals: 2015-2017
Pediatric Drug Approvals: 2011-2014
Phase III Completed Pediatric Drugs: 2015-2017 (As of July 2017)
Ongoing Phase III Pediatric Drugs Clinical Trials: 2015-2017 (As of July 2017)
Potential for Pediatric Drugs Against Obesity-related Conditions

Table 16. Top 10 Countries with the Highest Proportion of Overweight Children (includes corresponding Graph/Chart)

List of Pediatric Drugs for Congestive Heart Failure Treatment
Recent Findings to Help Save Children’s Lives
Challenges of Pediatric Drug Development: Formulation Problems and Ethical Constraints of Clinical Trials
Financial Enticement for Drug Makers to Conduct Dedicated Pediatric Trials
Modeling & Simulation – A Powerful Tool for Pediatric Clinical Study Sponsors
Pharmacometrics Approaches Gain Traction Among US and EU Researchers
Challenges Associated with Adoption of Pharmacometric Approach
Guidelines for Conducting Ethically Correct Clinical Trials
Pediatric Drug Market – Is Off-label Prescription Justified?
Indian Drug Manufacturers Develop Pneumococcal Conjugate Vaccine
High Vaccination Costs: A Major Hindrance for Pneumonia Vaccination
Vaccine Refusal by Parents – A Growing Trend in the US Market
Orphan Drugs for Pediatric Use Gain Popularity
List of FDA Approved Orphan Drugs: 2015-2016
List of FDA Designated Orphan Drugs: 2015-2017
Pediatric Review Vouchers Foster Innovation in Rare Pediatric Drugs
Need for Higher Focus on Fixed-Dose Combination for Pediatric HIV Infections
Approved Pediatric Antiretroviral Drugs for HIV Treatment
Highly Fragmented Growth Hormone Market

3. PEDIATRIC VACCINES MARKET

Table 17. Number of Reported Cases for Vaccine-Preventable Diseases Globally: 2013-2016

Table 18. Percentage of Target Population Vaccinated, by Antigen: 2013-2015 (includes corresponding Graph/Chart)

Immunization Coverage

Table 19. Routine Immunization Coverage (2015): Percentage of Live Births/New Borns/Infants/ Children Vaccinated by Select Region

Market Share of Leading Pediatric Vaccine Manufacturers

Table 20. Global Pediatric Vaccines Market by Leading Players (2016E): Percentage Market Share Breakdown of Dollar Sales for GlaxoSmithKline, Sanofi-Pasteur, Merck, Pfizer, and Others (includes corresponding Graph/Chart)

Phase III Completed Pediatric Vaccines: 2015-2017 (As of July 2017)
Ongoing Phase III Pediatric Vaccines Clinical Trials: 2015-2017 (As of July 2017)
Pediatric Vaccine Types
Hemophilus Influenza Type B Vaccine
Available Hib and Combination Vaccines
Diphtheria/Tetanus/Pertussis Vaccines (DTaP Vaccines)
Available DTaP and Combination Vaccines

Table 21. Global DTP3 Immunization Coverage: 2005-2015 (includes corresponding Graph/Chart)

Table 22. DTP3 Immunization Coverage, 2015 (includes corresponding Graph/Chart)

Hepatitis A Vaccine
Hepatitis B Vaccine
Measles/Mumps/Rubella (MMR) Vaccines
Rotavirus Vaccines
Polio Vaccines
Varicella Virus Vaccine (VAR)
Pneumococcal Disease Vaccines
Meningococcal Vaccines
Combination Vaccines
Rising Women Workforce Propels Pediatric Vaccines Growth

Table 25. Female Employment-to-Population Ratio (%): 2002, 2007, 2012, & 2016 (includes corresponding Graph/Chart)

4. PEDIATRIC DISEASES – OVERVIEW, STATISTICS & TREATMENT

Influenza
Treatment
Urinary Tract Infection (UTI)
Prevalence
Treatment
Mumps
Complications Related to Mumps
Prevention of Mumps in children
Incidence
Candidiasis
Fifth Disease
Molluscum Contagiosum
Roseola
Tetanus
Whooping Cough
Allergy and Respiratory Diseases
Prevalence Statistics
Diphtheria
Incidence and Mortality Statistics
Upper Respiratory Infection (Common Cold)
Diagnosis & Treatment
Measles
Statistics
Asthma
Prevalence
Central Nervous System Disorders
Mental Disorders
Attention Deficit Hyperactivity Disorder
Prevalence
Depression
Prevalence
Epilepsy
Epilepsy Treatment
Incidence and Prevalence of Epilepsy in the US
Hormonal Disorders
Diabetes Mellitus
Hypothyroidism
Hypothyroidism in Infants and Children
Symptoms and Diagnosis
Treatment of Hypothyroidism in Children
Precocious Puberty
Symptoms and Signs
Signs of Early Puberty in Girls and Boys
Treatment
Hypopituitarism
Treatment
Lymphocytic Thyroiditis
Symptoms
Treatment
Other Diseases
Cardiovascular Diseases
Cancers

5. LIST OF SELECT FDA APPROVED PEDIATRIC DRUGS

6. PRODUCT INTRODUCTIONS/APPROVALS

Actelion Obtains 'Epoprostenol Act' Label Extension for Pediatric PAH Patients in Japan
FDA Approves Merck’s KEYTRUDA (pembrolizumab)
Novartis Announces FDAs Acceptance of Company’s CAR-T Cell Therapy BLA for Pediatric and Young Adult Patients with r/r B-cell ALL
Boehringer Ingelheim’s Tiotropium Respimat Receives FDA Approval Expansion for Maintenance Treatment of Asthma in Children
Sanofi Pasteur terminates a Vaccine Joint-venture with MSD
ViiV Healthcare Announces the Changed Opinion of CHMP to Lower the Age and Weight Limit for Tivicay (dolutegravir) in Children and Adolescents Living with HIV in Europe
Shire Announces FDA Approval of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] for Use in Children and Surgical settings
Pfizer Inc. Announces PHASE 3 TRIALs Positive Results of LYRICA (PREGABALIN) Capsules CV and Oral Solution CV for Treating Pediatric Epilepsy Patients
Pfizer’s Prevenar 13 Receives Approval for Use in Infants and Children in China
Simponi Receives European Commission Approval for Treatment of Polyarticular Juvenile Idiopathic Arthritis
Sanofi Pasteur Launches India's first innovative 6-in-1 vaccine
Shire launches pediatric indication for immunodeficiency treatment HyQvia in Europe
Novo Nordisk’s NovoRapid receives positive opinion from CHMP for extended use in European Union for children as young as one year old
Boehringer Ingelheim Announces the Ability of Tiotropium Respimat for improving lung function in children aged 6-11
FDA Approves BLINCYTO (blinatumomab) for Use in Pediatric Patients with Philadelphia Chromosome-Negative Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
FDA Approves Genentech’s Xolair (omalizumab) for Allergic Asthma in Children
Novartis Receives EU Approval for Revolade as First-in-class Therapy for Children Aged 1 year and above with Chronic ITP
Pandemic Influenza Vaccine Receives Positive Opinion from CHMP
GSK’s Advair Diskus Exhibits Primary Endpoint in paediatric ‘LABA’ Safety Study
FDA Accepts Amgen's Supplemental Biologics License Application (sBLA) for The Expanded Use Of Enbrel (Etanercept) To Treat Pediatric Patients with Chronic Severe Plaque Psoriasis
Genentech’s supplemental Biologics License Application (sBLA) Receives Acceptance from FDA for reviewing Xolair (omalizumab)
Shire Partner, Shionogi, Submits New Drug Application in Japan for ADHD treatment for children
Shire Reports Topline Results from Phase 2 Studies in Children with Alagille Syndrome
FDA approves first drug to treat a rare enzyme disorder in pediatric and adult patients for Immediate Release
Sanofi K. K. and Aptalis Pharmaceutical Technologies Launches Allegra Dry Syrup 5% in Japan
Sanofi Pasteur Announces Availability of First Doses of Injectable Polio Vaccine ShanIPV(TM) in Near Future for Indian Infants
Shire receives CHMP’s Positive Opinion in Europe for INTUNIV
Novo Nordisk’s Levemir Receives Positive Opinion from CHMP for Extended use in Children as Young as one Year Old

7. RECENT INDUSTRY ACTIVITY

Johnson & Johnson Acquires Actelion
Sanofi Collaborates with MedImmune for development and Commercialization of Monoclonal Antibody for Preventing RSV
GSK Intends to Opens a New Global Vaccines R&D Center in Rockville, MD, USA
Lupin and Monosol Rx Enters into Licensing Agreement for Developing Multiple Pediatric-Focused Products
ICGEB & Sun Pharma Enters into New Exclusive Collaboration to Develop Novel Dengue Vaccine for India & Global Markets
Actelion Initiates Phase III Study of Macitentan (Opsumit) for treating Children with PAH
Shire and Cincinnati Children’s Establishes Rare Disease Research Collaboration

8. FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (USA)
Allergan, Inc. (USA)
Amgen, Inc. (USA)
AstraZeneca Plc. (UK)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (USA)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche Ltd (Switzerland)
Genentech, Inc. (USA)
GlaxoSmithKline plc. (UK)
Janssen Biologics B. V. (USA)
Actelion Pharmaceuticals Ltd (Switzerland) (A Janssen Pharmaceutical Company)
Merck & Co., Inc. (USA)
Novartis AG (Switzerland)
Novo Nordisk A/S (Denmark)
Pfizer, Inc. (USA)
Sanofi S. A (France)
Shionogi Inc. (USA)
Shire Pharmaceuticals Group Plc. (UK)

9. GLOBAL MARKET PERSPECTIVE

Table 26. World Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 27. World Historic Review for Pediatric Drugs and Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 28. World 14-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Share Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Pediatric Vaccines Market by Therapeutic Segment

Table 29. World Recent Past, Current & Future Analysis for Pediatric Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 30. World Historic Review for Pediatric Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 31. World 14-Year Perspective for Pediatric Vaccines by Geographic Region - Percentage Share Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 32. World Recent Past, Current & Future Analysis for Pediatric Hormones by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 33. World Historic Review for Pediatric Hormones by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 34. World 14-Year Perspective for Pediatric Hormones by Geographic Region - Percentage Share Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 35. World Recent Past, Current & Future Analysis for Pediatric Allergy & Respiratory Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 36. World Historic Review for Pediatric Allergy & Respiratory Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 37. World 14-Year Perspective for Pediatric Allergy & Respiratory Drugs by Geographic Region - Percentage Share Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 38. World Recent Past, Current & Future Analysis for Pediatric Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 39. World Historic Review for Pediatric Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 40. World 14-Year Perspective for Pediatric Antibiotics by Geographic Region - Percentage Share Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 41. World Recent Past, Current & Future Analysis for Pediatric CNS Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 42. World Historic Review for Pediatric CNS Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 43. World 14-Year Perspective for Pediatric CNS Drugs by Geographic Region - Percentage Share Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 44. World Recent Past, Current & Future Analysis for Other Pediatric Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 45. World Historic Review for Other Pediatric Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 46. World 14-Year Perspective for Other Pediatric Drugs by Geographic Region - Percentage Share Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 47. World Recent Past, Current & Future Analysis for Pediatric Vaccines by Type - Combinations, Hepatitis, MMR, Varicella, Poliovirus, Pneumococcal, and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 48. World 9-Year Perspective for Pediatric Vaccines by Type - Percentage Share Breakdown of Dollar Sales for Combinations, Hepatitis, MMR, Varicella, Poliovirus, Pneumococcal, and Other Markets for Years 2017 & 2024 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis
Pediatric Drugs Market in the US
Major Diseases Afflicting Children in the US
Incidence of Diabetes Mellitus on Rise in the US
Pediatric Vaccines Market

2017 VACCINE RECOMMENDATIONS RELEASED BY CDC AND AAP

The United States Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger— United States, 2017.
The United States Catch-up immunization schedule for persons aged 4 months through 18 years who start late or who are more than 1 month behind— United States, 2017
Dealing with Child Immunization and Parental Reluctance
Regulatory Environment
Evolution of Regulations for Pediatric Drug Testing
PREA and BPCA – A Boon for Pharma Companies
Affordable Care Act Favoring the US Pediatric Drugs Market
Child Population & Birth Rates

Table 49. Birth Rates in the US: Breakdown of Number of Births (per ‘000 Population) for the Years 1990, 1995, 2000, 2005, 2010, and 2015 (includes corresponding Graph/Chart)

Opportunity Indicator

Table 50. Routine Immunization Coverage in the US (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)

Product Launches/Approvals
Strategic Corporate Developments
Focus on Select Major Players
B. Market Analytics

Table 51. The US Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 52. The US Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class -Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 53. The US 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

2. CANADA

A. Market Analysis
Opportunity Indicator

Table 54. Canadian Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)

B. Market Analytics

Table 55. Canadian Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 56. Canadian Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 57. Canadian 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

3. JAPAN

A. Market Analysis
Opportunity Indicator

Table 58. Japanese Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)

Product Launches/Approvals
B. Market Analytics

Table 59. Japanese Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 60. Japanese Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 61. Japanese 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis

Table 62. Proportion of Children in the 0-15 Years Age Group by Country in Europe (2016) (includes corresponding Graph/Chart)

Phase III Completed Clinial Trials for Pediatric Drugs: As of July 2014
Pediatric Drugs in Phase III Clinical Trials: As of July 2014
Product Launches/Approvals
B. Market Analytics

Table 63. European Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 64. European Historic Review for Pediatric Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 65. European 14-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Share Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 66. European Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 67. European Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 68. European 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4A. FRANCE

A. Market Analysis
Opportunity Indicator

Table 69. French Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)

Focus on Select Major Player
B. Market Analytics

Table 70. French Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 71. French Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 72. French 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4B. GERMANY

A. Market Analysis
Opportunity Indicator

Table 73. German Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)

Product Launches/ Approvals
Select Major Player
B. Market Analytics

Table 74. German Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 75. German Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 76. German 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4C. ITALY

A. Market Analysis
Opportunity Indicator

Table 77. Italian Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)

B. Market Analytics

Table 78. Italian Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 79. Italian Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 80. Italian 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4D. THE UNITED KINGDOM

A. Market Analysis
Opportunity Indicator

Table 81. The UK and Northern Ireland Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/ Children Vaccinated (includes corresponding Graph/Chart)

Product Launches/Approvals
Focus on Select Major Players
B. Market Analytics

Table 82. The UK Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 83. The UK Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 84. The UK 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4E. SPAIN

A. Market Analysis
Opportunity Indicator

Table 85. Spanish Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)

B. Market Analytics

Table 86. Spanish Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 87. Spanish Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 88. Spanish 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4F. RUSSIA

A. Market Analysis
Opportunity Indicator

Table 89. Russian Federation Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/ Infants/Children Vaccinated (includes corresponding Graph/Chart)

B. Market Analytics

Table 90. Russian Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 91. Russian Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 92. Russian 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4G. REST OF EUROPE

A. Market Analysis
Product Launches/ Approvals
Strategic Corporate Development
Focus on Select Major Players
B. Market Analytics

Table 93. Rest of Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 94. Rest of Europe Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 95. Rest of Europe 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. Market Analysis

Table 96. Proportion of Children in the 0-15 Years Age Group by Country in Asia-Pacific (2016) (includes corresponding Graph/Chart)

Burgeoning Middle Class Population in Asia Bodes Well for Market Growth

Table 97. World Middle Class Population (2012 & 2030): Percentage Share Breakdown by Region - North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (includes corresponding Graph/Chart)

B. Market Analytics

Table 98. Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 99. Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 100. Asia-Pacific 14-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Share Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 101. Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 102. Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 103. Asia-Pacific 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5A. CHINA

A. Market Analysis
Chinese Market Outlook
Opportunity Indicator

Table 104. Chinese Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)

Growing Pediatric Market in China

Table 105. Chinese Population (2000-2016): Breakdown of Population by Age Group (includes corresponding Graph/Chart)

China Sets Eyes on Supporting Pediatric Drugs Market
Expediting R&D and Drug Review Process
Strengthening Policies Related to Pediatric Drug Production and Supply
Enhancing Clinical Usage of Pediatric Drugs
Implementation of Safety and Quality Control Measures
Harmonizing Chinese and Western Drugs
Increasing Public Awareness
Product Approval
B. Market Analytics

Table 106. Chinese Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 107. Chinese Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 108. Chinese 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5B. INDIA

A. Market Analysis
Opportunity Indicator

Table 109. Indian Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)

Pediatric Drug Development in India
Higher Usage of Pediatric Drugs than Vaccines in the Indian Market
Measles Rubella (MR) Vaccine Launched for Dual Protection in India
Three New Children Vaccines under India’s Universal Immunization Programme
Product Launch/Approval
Strategic Corporate Development
B. Market Analytics

Table 110. Indian Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 111. Indian Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 112. Indian 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5C. REST OF ASIA-PACIFIC

A. Market Analysis
Opportunity Indicator

Table 113. Routine Immunization Coverage in Republic of Korea (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)

B. Market Analytics

Table 114. Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 115. Rest of Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 116. Rest of Asia-Pacific 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

6. LATIN AMERICA

A. Market Analysis

Table 117. Proportion of Children in the 0-15 Years Age Group by Country in Latin America (2016) (includes corresponding Graph/Chart)

Opportunity Indicator

Table 118. Brazilian Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)

B. Market Analytics

Table 119. Latin American Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 120. Latin American Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 121. Latin American 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

7. REST OF WORLD

A. Market Analysis
Africa
Kenya Introduces Advanced Drugs for Treatment of TB in Children
Opportunity Indicator

Table 122. Proportion of Children in the 0-15 Years Age Group by Country in the Middle East (2016) (includes corresponding Graph/Chart)

Table 123. Saudi Arabian Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)

Table 124. South African Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)

Table 125. Central African Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)

B. Market Analytics

Table 126. Rest of World Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 127. Rest of World Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 128. Rest of World 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 90 (including Divisions/Subsidiaries - 103)
The United States (53)
Canada (3)
Japan (7)
Europe (33)
  France (3)
  Germany (1)
  The United Kingdom (6)
  Italy (1)
  Rest of Europe (22)
Asia-Pacific (Excluding Japan) (7)